TY - JOUR
T1 - Randomized, split-body, single-blinded clinical trial of topical broccoli sprout extract
T2 - Assessing the feasibility of its use in keratin-based disorders
AU - Kerns, Michelle L.
AU - Guss, Lark
AU - Fahey, Jed
AU - Cohen, Bernard
AU - Hakim, Jill M.C.
AU - Sung, Sarah
AU - Lu, Rosemary G.
AU - Coulombe, Pierre A.
N1 - Publisher Copyright:
© 2016 American Academy of Dermatology, Inc.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background Epidermolysis bullosa simplex is a skin-blistering disorder caused by mutations in keratin (K)14 or K5. Treatment with nuclear factor (erythroid-derived 2)-like 2 inducer sulforaphane ameliorated skin blistering in Krt14-null mice, correlating with induction of K17. To be therapeutically useful for epidermolysis bullosa simplex, topical broccoli sprout extract (BSE), enriched for sulforaphane, would ideally induce the expression of homologous keratins (eg, K6, K17, K16) in the basal layer of human epidermis without impacting expression of defective keratins (K5/K14). Objective The purpose of this 1-week, randomized, split-body, single-blinded, placebo-controlled trial was to assess the impact of BSE on keratin expression. Methods Five subjects (34-71 years old) applied BSE (500 nmol of sulforaphane/mL) or vehicle alone to the inner aspect of the arm daily. Expression of keratin, nuclear factor (erythroid-derived 2)-like 2, and other markers was assessed using reverse transcription-polymerase chain reaction and indirect immunofluorescence. Results One subject (age 71 years) was excluded a posteriori because of poor tissue quality. Topical BSE activated nuclear factor (erythroid-derived 2)-like 2 and up-regulated K17 in the epidermis of all subjects, had variable effects on K16 and K6 expression, and did not alter expression of K14 or K5. Limitations Small sample size is a limitation. Conclusion BSE represents an attractive therapeutic candidate for K14-associated epidermolysis bullosa simplex.
AB - Background Epidermolysis bullosa simplex is a skin-blistering disorder caused by mutations in keratin (K)14 or K5. Treatment with nuclear factor (erythroid-derived 2)-like 2 inducer sulforaphane ameliorated skin blistering in Krt14-null mice, correlating with induction of K17. To be therapeutically useful for epidermolysis bullosa simplex, topical broccoli sprout extract (BSE), enriched for sulforaphane, would ideally induce the expression of homologous keratins (eg, K6, K17, K16) in the basal layer of human epidermis without impacting expression of defective keratins (K5/K14). Objective The purpose of this 1-week, randomized, split-body, single-blinded, placebo-controlled trial was to assess the impact of BSE on keratin expression. Methods Five subjects (34-71 years old) applied BSE (500 nmol of sulforaphane/mL) or vehicle alone to the inner aspect of the arm daily. Expression of keratin, nuclear factor (erythroid-derived 2)-like 2, and other markers was assessed using reverse transcription-polymerase chain reaction and indirect immunofluorescence. Results One subject (age 71 years) was excluded a posteriori because of poor tissue quality. Topical BSE activated nuclear factor (erythroid-derived 2)-like 2 and up-regulated K17 in the epidermis of all subjects, had variable effects on K16 and K6 expression, and did not alter expression of K14 or K5. Limitations Small sample size is a limitation. Conclusion BSE represents an attractive therapeutic candidate for K14-associated epidermolysis bullosa simplex.
KW - broccoli sprout extract
KW - epidermolysis bullosa simplex
KW - keratin
KW - nuclear factor (erythroid-derived 2)-like 2
KW - sulforaphane
UR - http://www.scopus.com/inward/record.url?scp=85007199309&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007199309&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2016.10.009
DO - 10.1016/j.jaad.2016.10.009
M3 - Article
C2 - 27889290
AN - SCOPUS:85007199309
SN - 0190-9622
VL - 76
SP - 449-453.e1
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 3
ER -